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The West African Ebola virus outbreak underlined the importance of delivering mass diagnostic capability
outside the clinical or primary care setting in eﬀectively containing public health emergencies caused by
infectious disease. Yet, to date, there is no solution for reliably deploying at the point of need the gold
standard diagnostic method, real time quantitative reverse transcription polymerase chain reaction (RT-
qPCR), in a laboratory infrastructure-free manner. In this proof of principle work, we demonstrate direct
performance of RT-qPCR on fresh blood using far-red ﬂuorophores to resolve ﬂuorogenic signal
inhibition and controlled, rapid freeze/thawing to achieve viral genome extraction in a single reaction
chamber assay. The resulting process is entirely free of manual or automated sample pre-processing,
requires no microﬂuidics or magnetic/mechanical sample handling and thus utilizes low cost
consumables. This enables a fast, laboratory infrastructure-free, minimal risk and simple standard
operating procedure suited to frontline, ﬁeld use. Developing this novel approach on recombinant
bacteriophage and recombinant human immunodeﬁciency virus (HIV; Lentivirus), we demonstrate
clinical utility in symptomatic EBOV patient screening using live, infectious Filoviruses and surrogate
patient samples. Moreover, we evidence assay co-linearity independent of viral particle structure that
may enable viral load quantiﬁcation through pre-calibration, with no loss of speciﬁcity across an 8 log-
linear maximum dynamic range. The resulting quantitative rapid identiﬁcation (QuRapID) molecular
diagnostic platform, openly accessible for assay development, meets the requirements of resource-
limited countries and provides a fast response solution for mass public health screening against
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The 2013–2016 Ebola virus (EBOV) outbreak resulted in over
28 500 conrmed cases across three continents with an overall
mortality rate of 39.5% (http://www.who.int/mediacentre/news/
releases/2016/ebola-zero-liberia/en/). Unlike previous
outbreaks, lack of preparedness in West Africa, local customs
that facilitated transmission, and the generally poor healthcare
infrastructure were key to the unprecedented size of the
outbreak. An international emergency response was therefore
necessary to arrest what rapidly became a global health and
security threat. Thus, at the peak of transmission in August
2014, the World Health Organization (WHO) declared the
outbreak a public health emergency of international concern
(PHEIC; http://www.who.int/mediacentre/news/statements/
2014/ebola-20140808/en/). It quickly became clear that success
in containing the outbreak would pivot on three actions: (1)
reliable diagnosis of suspected/probable cases i.e. symptomaticThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineindividuals; (2) quick isolation of patients conrmed as infected
with EBOV, and; (3) eﬀective contact tracing.1
Unfortunately, symptomatic, suspected cases were diﬃcult
to diﬀerentially diagnose against other causative agents of
hemorrhagic fever, as symptoms were generally non-specic
and common to other endemic, high incidence infections
such as malaria, yellow fever, and Lassa fever. Furthermore,
epidemiological information, where available, only marginally
contributed to patient triage by increasing EBOV disease risk
potential from ‘suspected’ to ‘probable’. Thus, it became
essential to obtain explicit, clinical diagnostic grade evidence of
active EBOV infection as quickly as possible aer patient
presentation. Nucleic acid amplication testing (NAAT) using
thermal cycling, uorescent probes and real time, quantitative
reverse transcription polymerase chain reaction (RT-qPCR) was
quickly recognized as the most reliable clinical diagnostic
solution for symptomatic EBOV patients.2 Thus, studies during
previous outbreaks3–5 and data emerging from West Africa4
reaﬃrmed that patients would present to triage only when
symptoms became intense, corresponding to high viraemia
levels ranging 105–1010 genome equivalents per ml (GE per ml)
of whole blood.
Importantly, RT-qPCR is an internationally adopted in vitro
diagnostic (IVD) technology considered robust, sensitive, and
highly specic. Unlike most other territories, in the USA the
Food and Drug Administration (FDA) presently regulates strin-
gently both IVD thermal cycler instruments and associated IVD
assay kits through extensive clinical trials before issuing
marketing authorization. Furthermore, diagnostic services
based on NAAT are provided only through FDA-regulated labo-
ratories; the services also cover infectious disease agent diag-
nostics, including a multitude of RNA viruses.6 This regulatory
framework applies whether the diagnostic test is available as an
independently marketed IVD kit or an assay developed in-house
in the regulated laboratory using regulated reagents. Such
measures enhance diagnostic service reliability, a requirement
important in the context of highly infectious disease such as
hazard group 3 and 4 pathogens.
Implementation of NAAT diagnostics for EBOV disease was
spearheaded by the August 2014 FDA Emergency Use Authori-
zation (EUA) of the EZ1 Taqman® assay which uses FAM-
labelled uorescent probes for RT-qPCR undertaken on one
of several FDA-approved thermal cyclers (http://www.fda.
gov/downloads/MedicalDevices/Safety/EmergencySituations/
UCM418799.pdf). This molecular test involves the quantitative
detection of two RNA substrates: the EBOV glycoprotein (GP)7
gene encoded in the negative RNA genome of EBOV, and the
human ribonuclease P (RP) transcript which is found at high
levels in human biouid samples, as an endogenous/process
control.8 To date, this so-called Trombley assay7 remains the
gold standard of diagnostic care7,9,10 used by public health
agencies worldwide and is reported to be the most sensitive and
specic for semi-quantitative EBOV diagnosis in viraemic, i.e.
symptomatic patients.10 Thus, the Trombley assay features
a 0.0001 plaque forming unit per reaction (PFU per reaction)
lower limit of detection (LLOD), across a 5 log-linear dynamic
range (LDR),7,9 and analytical specicity against human RNA,This journal is © The Royal Society of Chemistry 2017and 75 other pathogens (http://www.fda.gov/downloads/
MedicalDevices/Safety/EmergencySituations/UCM408334.pdf).
Of note, the qualication and performance data of this assay do
not pertain to the reaction substrate, the EBOV RNA genome,
but rather the amount of live virus in the sample. This relates to
the use of infectious virus quantication methods in classical
virology (PFU quantication assays),11 which are medically
valuable in informing the risk of infection/transmission, rather
than the biochemically relevant assay substrate concentration
reported by NAAT. Yet studies with in vitro produced virus9,12
and macaque infection models13 indicate the viral genomes
might be 10-fold12 to 10 000-fold9 higher than infectious virions
in a given sample. This has been evidenced across many hazard
group 3 and 4 viruses, and has been associated to the extent of
virus passage in vitro.13 Clinical data remains limited given the
preference for immediate virus inactivation for health and
safety reasons.
Unfortunately, the entire Trombley procedure is slow,
laboratory-based, and has considerable safety implications.
Thus, venous blood is the biological sample of choice, but the
large volumes needed (3.5 ml) increase the risk of uncontrolled
bleeding for patients exhibiting hemorrhagic symptoms. The
samples also present a risk of infection to the healthcare staﬀ
collecting them and the diagnostic laboratory personnel
analyzing them, making extensive safety training essential in
reducing transmission. Notwithstanding safety concerns, the
Trombley assay procedure further necessitates considerable
technical expertise involving multiple manual steps operating
expensive laboratory infrastructure and mains-powered instru-
mentation, using expensive consumables stored constantly at
4 C. Appropriately equipped facilities were scant in West Africa
and the technology was not suited to laboratory-free eld
deployment in rural regions where need was at its highest.2 In
addition, at US$100, the cost per patient14 exceeded by up to
tenfold the annual, per capita healthcare expenditure in the
region.15 Moreover, the time-to-results, at best 5–8 hours from
sample receipt, restricted throughput capacity and presented
additional infection risks to EBOV-free patients awaiting results
whilst in triage. Overall, at the peak of transmission, assay
complexity, cost, and lack of speed to molecular diagnosis
hampered the eﬀorts to stave oﬀ transmission.
To address these challenges many industrial and academic
groups responded to calls for solutions in line with the WHO
ASSURED criteria16 relevant to resource limited settings. Thus,
the ideal diagnostic test should be aﬀordable, sensitive,
specic, user-friendly, robust, rapid, equipment-free and
deliverable to those in need – i.e. usable in the eld with
minimal requirements for additional resources. Ideally, this
would also involve minimal biouid volumes, such asmicroliter
drops of blood analysed in situ by digital venipuncture, not
dissimilar to over-the-counter, point-of-need glucometers. To
date, the most clinically advanced, close-to-patient NAAT IVDs
still require powered instrumentation, a fully equipped labo-
ratory setting (xed or mobile), training associated to multiple
handling steps starting with 3.5 ml of venous blood, and
consumables still far too costly for the countries most aﬀected
by such tropical disease.2,10,17Chem. Sci., 2017, 8, 7780–7797 | 7781
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View Article OnlineHere, we report our eﬀorts to address the need for quanti-
tative, rapid and reliable, molecular diagnosis of EBOV disease
in symptomatic patients arriving at triage, under the 12 month
Emergency Call Research for Health in Humanitarian Crisis
(r2hc) program of the Enhancing Learning and Research for
Humanitarian Assistance (ELRHA) organization. Taking into
account reports that quantitative PCR (qPCR) is possible in
reactions containing blood,18,19 we present evidence that this
extends to RT-qPCR retaining quantitative diagnostic value
without the need for substantial formulation/enzyme modi-
cations, provided far-red dyes are used to overcome the uo-
rogenic inhibition eﬀect of blood and the minimal impact on
sensitivity remains clinically acceptable. We further evaluate
the utility of controlled freezing and thawing cycles in disrupt-
ing virion structures to release viral genomes directly in blood
samples as an energy and engineering-eﬃcient means of elim-
inating manual or automated RNA extraction and purication.
We further present the development of an instrument and
computational approach compatible with parallel detection of
multiple far-red dyes, engineered for eld deployment at the
point of need, in a laboratory infrastructure-free manner, and
with minimal end-user training requirements. Finally, we
determine the performance of this approach in detecting and
quantifying EBOV against the gold standard, laboratory-based
Trombley assay, within the context of screening symptomatic
patients in a triage setting.
Results
Benchmark assay system performance
Given the emerging evidence that the Trombley GP assay per-
formed better against a number of other RT-qPCR assays for
EBOV,7,9,10 and to focus our eﬀorts, we adopted the Trombley
assays for the EBOV GP and NP genes in our work. Moreover, to
overcome limited biosafety level 4 (BSL4) facility and staﬀ
availability due to increased screening services demand, we
used surrogate EBOV templates. We reasoned against chemi-
cally synthesized RNA as a template because blood nucleases
rapidly degrade such biomaterials at ambient temperatures,20
which could prove problematic with minimal assay formula-
tions. On the other hand, de novo construction of in vitro
produced, non-infectious, and/or replication-decient EBOV
virions,21 an approach common formany well-studied species of
mammalian viruses, was actively discouraged outside high
containment for reasons of health, safety, and biosecurity. We
thus elected to use commercially available recombinant MS2
coliphage as our primary surrogate template (AR14), despite the
robustness of this virion compared to the easily fragmentable
nature of lovirus particles,22 and pseudotyped lentivirus (PV)
based on HIV manufactured in-house as a fallback template
(see ESI, Fig. S1†).23
To benchmark Trombley assay performance with these
standards, we performed the plate-based EZ1 kit standard
operating procedure (SOP) on an ABI7500 real time thermal
cycler.7 We thus used healthy volunteer blood freshly collected
by supercial venipuncture, spiked with AR14 to a nal
concentration of 1.67  1011 GE per ml of blood. Viral RNA was7782 | Chem. Sci., 2017, 8, 7780–7797then extracted using the QIAamp Viral RNA Mini Kit (Qiagen,
Manchester, UK), puried extracts were serially diluted with
nuclease-free water and 5 ml volumes were assayed in triplicate.
The results demonstrated independent amplication eﬃcien-
cies for the GP and NP assays (98.0% and 102%, respectively)
despite the use of the same template, resulting in distinct curve
ts as determined by Akaike's informative criteria test (Fig. 1).
The high concentration of AR14, however, allowed us to
demonstrate a linear dynamic range (LDR) for both assays 3 logs
higher than that reported previously.7 Moreover, the 6.67
genome equivalent per reaction (GE per reaction) lower limit of
detection (LLOD) and low variability between technical repli-
cates, as demonstrated through 95% condence bands across
the dilution series (% CV < 2.09% for GP and < 3.41% for NP),
set performance standards for forward work. Furthermore, aer
generating PV constructs containing the Trombley assay target
sequences corresponding to the 1976 EBOV Yambuka-Ecran
reference genome (PV76) and the 2014 EBOV Guinea Makona
reference genome (PV14), we conrmed that the single nucle-
otide polymorphisms identied within the West African
outbreak isolate24 had limited impact on diagnostic assay reli-
ability (see ESI, Fig. S1, Tables S1 and S2†).RT-qPCR proceeds but is uorogenically inhibited by blood
not treated with anticoagulants
Previous reports18,19,25 indicated that PCR containing whole
blood may proceed in the context of enabling mutations in the
Taq DNA polymerase (OmniTaq mutant)18,19 or with at least one
commercially available, research-grade polymerase supple-
mented with reaction enhancers.19,25 However, implementation
reliability concerns had been independently expressed.25
Importantly, qPCR with SYBR Green I nucleic acid stain (520 nm
emission peak) was only achieved with their OmniTaq enzyme18
and by overcoming the inhibitory eﬀect of blood on uo-
rogenicity dose-dependently, e.g. by using 64 higher concen-
trations of dye for a reaction spiked with 10% v/v blood.
Notably, this work involved blood and plasma treated with anti-
coagulants which are known PCR inhibitors, and samples were
freeze–thawed up to ve times. Use of green dye-labelled
Taqman® probes (CAL Fluor 540 nm) was later shown by the
same group to require a complex PCR enhancer cocktail to
achieve detection of as little as 7 genome equivalents per
microliter (GE per ml) of DNA template with their OmniTaq
polymerase in the presence of blood. Although the authors
demonstrated that the cocktail could be useful for other poly-
merases in end-point PCR assays, they did not discuss its' use in
RT-qPCR. Encouraged by these reports, and working in parallel
to constructing the PV standards, we investigated whether the
blood compatibility of PCR could be extended to RNA templates
and RT-PCR using similar, well-characterized assays.6,27
However, in line with our projected application of analyzing
patient blood immediately upon collection, we dispensed with
anticoagulants and blood storage altogether. Instead, we spiked
fresh human blood directly into reactions by obtaining it
through digital venipuncture ad hoc. We thus assembled one-
step RT-qPCR reactions with a commercially available TaqThis journal is © The Royal Society of Chemistry 2017
Fig. 1 Trombley qRT-PCR assay performance is not aﬀected by Ebola virus genetic drift. Serially diluted RNA extracts of HIV-1 pseudotyped
Lentiviruses encoding the 1976 (a, b) and 2014 (c) assay target sequences (PV76 and PV14, respectively) for the Trombley (a, c) glycoprotein (GP)
and (b, d) nucleoprotein (NP) assays were subjected to one-step qRT-PCR on an ABI7500 using the EZ1 SOP. These tests were repeated on RNA
extracts of the AR14 template (d) to demonstrate an 8 log LDR with independent curve ﬁts per assay (<0.01% probability of single curve ﬁt,
Akaike's Informative Criteria test). Means  95% conﬁdence bands are shown.
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View Article Onlinepolymerase (GoTaq® G2 Flex; Promega, Inc) or the blood-
tolerant OmniTaq 2 (DNA Polymerase Technology, Inc.), using
the manufacturer's mastermix, respectively, and 5 U per reac-
tion of GoScript® Moloney Murine Leukemia virus reverse
transcriptase (Promega). Importantly, although these master-
mix formulations remained proprietary, both suppliers
conrmed that neither formulation featured additives to over-
come PCR inhibitors. Working on wet ice, these reactions were
spiked with 4  108 copies of Escherichia coli MS2 phage RNA,
a FAM-labelled Taqman® probe (518 nm emission peak), and
increasing concentrations of fresh blood (Fig. 2). To our
surprise, our results indicated that RT-PCR successfully pro-
ceeded in the presence of blood with no obvious diﬀerences
between the hot-start, wild type Taq polymerase (Fig. 2a) and
the blood-adapted OmniTaq mutant (Fig. 2b). However, in both
cases, blood inhibited the uorogenic signal of the probe in
a concentration-dependent manner.
To determine whether this was a limitation of using uo-
rescently labelled probe detection chemistry, we evaluated
qPCR output with OmniTaq 2 against 5.5  103 copies of
lambda phage DNA, with a 10 higher Sybr Green I concen-
tration and up to 5% v/v blood, in line with the stain/blood
ratios indicated by Kermekchiev et al. As with the FAM-
labelled probe, this reaction format also exhibited blood
concentration-dependent inhibition of uorogenic signal
(Fig. S2†). Taken together, these results suggested that qPCR
and RT-qPCR might be achievable in the presence of blood
despite the inhibitory eﬀect of heme,25 with wild type DNAThis journal is © The Royal Society of Chemistry 2017polymerases in minimal mastermix formulations, provided no
anticoagulants were used during blood sampling, and the
inhibitory eﬀect of blood on dye uorogenicity could be
overcome.Far-red probe dyes and DNA stains enable RT-qPCR in blood
Given the spectral properties of blood and the better signal-to-
noise ratio of far-red dyes in other optical platforms such as
confocal microscopy and in vivo bioimaging,26 we hypothesized
far red/infrared uorophores might resolve the uorogenic
inhibition eﬀect of blood. To examine this hypothesis, the
emission spectra of a gamut of commercially available, far-red
nucleic acid stains (SYTO® family) and uorescent dyes
(CAL635, Quasar 670, Quasar 705) was assessed in the presence
or absence of fresh human blood (Fig. 2c). Using an Ocean
Optics Maya LSL uorimeter, we also took the opportunity in
these experiments to evaluate a variety of light sources: light
emitting diodes (Luxeon Phillips and Dragon Osram), ltered
white light sources and laser diodes. In these studies, use of
a laser diode source provided power output advantages that
were paralleled by several reduced engineering problems, such
as optical ber coupling and structural stability, and dispen-
sation of wavelength ltering requirements because lasers are
a discrete wavelength light source. Thus, use of this source
provided more excitation power to the vessel and, with
temperature stabilization, a more stable power and wavelength
that any of the power LEDs tested.Chem. Sci., 2017, 8, 7780–7797 | 7783
Fig. 2 Overcoming the dose-dependent inhibitory eﬀect of blood on qRT-PCR. Increasing amounts of fresh, unprocessed human blood
introduced into qRT-PCR reactions (0.0–5.0% v/v ﬁnal blood concentration) result in comparable dose-dependent inhibition of FAM-labelled
Taqman® probe-based RT-PCR ﬂuorogenicity (ampliﬁcation plateau) whether the Promega hot-start wild type Taq polymerase (a) or the blood-
optimisedOmniTaq 2 polymerase (b) is used in conjunction with an MMuLV reverse transcriptase to detect 4 108 copies of MS2 coliphage RNA.
Reaction progression is reported for each of two technical replicates in relative ﬂuorescence units (RFU) normalised to no template control (ve
c) against PCR cycle value. Far red/infrared ﬂuorescent dyes (c) and dye–quencher combinations (d) were screened by spectrophotometry under
620 nm laser diode simulation for utility in blood-containing reactions. The impact of blood on dye ﬂuorogenicity is expressed as the change
(DFN) in background-subtracted ﬂuorescence emission (RFU) in the presence and absence of human blood (mean of two technical replicates).
DDB: deep dark blue; VRH: Viridian Red High; VRL: Viridian Red Low; IWB: Iowa Black; BHQ: Black Hole Quencher.
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View Article OnlineThese studies also suggested that the emission peaks of far
red DNA stains were not consistently aﬀected, with some
exhibiting minimal inhibition (e.g. 13% for SYTO-17), and
others over resulting in 700% signal increase (SYTO-63), prob-
ably on account of the diﬀerential cell permeability and indi-
vidual binding properties of these stains to extracellular/
intracellular DNA and RNA (Fig. S3†). Thus, whilst SYTO-59
(ref. 27) and SYTO-16 (ref. 28) are cell-permeable DNA stains
used for leukocyte labelling in ow cytometry, SYTO-62 (ref. 29)
appears more sensitive to apoptotic cells. However, its selec-
tivity between DNA and RNA remains unclear. Moreover, SYTO-
59 (ref. 30 and 31) and SYTO-61 (ref. 30) eﬀectively enter
erythrocytes for the selective detection of Plasmodium falcipa-
rum infection, and SYTO-64 (ref. 32) can selectively stain
nucleated erythroid precursor cells, suggesting SYTO-59, -61
and -64 might be more selective for DNA over RNA. In our whole
blood assay format, however, SYTO-17 and SYTO-61 showed
comparable levels of peak signal loss, with SYTO-60, -62, and -63
exhibiting a substantial increase in peak signal levels, followed
by SYTO-59 and SYTO-64 (<20% peak signal increase). These
reports and our results therefore indicate SYTO-59, and -64
might have direct utility in substituting SYBR Green I on whole
blood qPCR and RT-qPCR, especially since SYTO-64 has been
previously demonstrated to have no impact on PCR eﬃciency.33
In stark contrast to the nucleic acid stains, the probe-
compatible Quasar 670, Quasar 705 and CAL635 dyes7784 | Chem. Sci., 2017, 8, 7780–7797consistently exhibited some 30–50% signal inhibition (Fig. 2c).
However, all three allowed for 15.2 dB, 9.98 dB and 15.9 dB
signal-to-noise ratios at their corresponding emission peaks
(Fig. S3A–C†), respectively, relative to background blood emis-
sion spectra (Fig. S3L†). Taken together, these results indicated
that the uorogenic inhibition eﬀect of blood might be
restricted to green dyes and perhaps even yellow-orange dyes,
making far red uorophores in general appropriate substitutes
for qPCR and RT-qPCR.
We proceeded to investigate this by procuring the EZ1 assay
GP probe conjugated to an array of far-red dye/quencher
combinations, in the presence of 8% v/v fresh human blood
(Fig. 2d and S4†). Using a custom optics array we conrmed
adequately detectable signal emission with all dye/quencher
combinations, although some data suggested quencher-
specic interactions with the biological matrix similar to
other reports involving cell34 and animal35 assays (see ESI†).
With signal nonetheless detected with all dyes, we triaged dye/
quencher pairs based on manufacturing cost, probe yield/
purication, and signal strength to arrive at Quasar 670/BHQ2
as the optimal substitute chemistry, particularly since stability
issues were also experienced with BHQ3 probes between
batches.
We thus proceeded to examine whether use of this
uorophore/quencher combination with the Trombley GP assay
(henceforth referred to as Trombley+ or GP+ assay; Table S3†)This journal is © The Royal Society of Chemistry 2017
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View Article Onlinewould aﬀect RT-qPCR reaction performance. Using RNA
extracts of AR14 (Fig. 3a), an analytical LLOD of 2 GE/reaction,
an 8 log LDR and a % CV < 2.73% was determined for the GP+
assay, with an 103% reaction eﬃciency and 91.6% probability of
single curve t against the FAM-labelled GP assay (Fig. 1) using
Akaike's Informative Criterion test. Importantly, these ndings
were reaﬃrmed by extending this analysis to PV14 (5.76  103
GE per ml LLOD; % CV < 1.26; 107% eﬃciency; 93.0% proba-
bility of single curve t; Fig. 3b) and external surrogate stan-
dards for EBOV NAATs36 (1.46  103 GE per ml LLOD; % CV <
2.81; 97.4% reaction eﬃciency; 94.9% probability of single
curve t Fig. 3c). Together, these results indicated that substi-
tution of green probe chemistries with blood compatible, far-
red dye/quencher pairs such as Quasar670/BHQ2 may facili-
tate rapid transition of pre-validated, probe-based assays to
whole blood-compatible RT-qPCR.Spectrophotometric signal detection for blood-containing
qPCR and RT-qPCR reactions
Individual assay performance notwithstanding, clinical diag-
nostic reliability pivots on the elimination, if possible, of false
positive/negative results. Plate-based NAATs such as the EZ1
assay minimize this risk by performing diagnostic reactions
parallel to sample control reactions; separate positive and
negative control reactions serve as process controls. Ensuring
comparable levels of diagnostic reliability with point of careFig. 3 Assay migration to the blood-compatible Trombley+ chemistry h
the Trombley+ GP assay chemistry (GP+) on 10-fold serial dilutions of R
and National Institute of Biological Standards and Controls (NIBSC) Ebo
tration-dependent 8 log-linear dynamic range and <10 genome equivale
free 20 ml (ABI7500) and 62.5 ml reactions (QuRapID) on AR14 RNA extr
kinetics and Ct (exponential onset) values. Means 95% conﬁdence band
spectrophotometric traces demonstrating example ampliﬁcation spectra
cycle (Z axis; depth) in the QuRapID reactions, with coloured lines corre
This journal is © The Royal Society of Chemistry 2017systems requires either multiplexed analysis for appropriate
controls within a single reaction chamber, or microuidic/
multiple reaction chamber detection of distinct templates.
We reasoned that a single reaction chamber solution would
maintain minimal consumable costs for an ASSURED-
compatible point of need system. Where DNA intercalator
stains such as SYBR Green I or SYTO-64 are used in a multi-
plexed assay approach, high resolution melting curve analysis
can report individual amplicon generation.37 On the other
hand, implementation of this methodology requires either
substantial, expert end-user input,38 signicant algorithm
training39,40 and/or high complexity, costly instrumentation.40
Moreover, our immediately relevant EBOV GP and RP assays in
the EZ1 kit involved probe-based detection. In these cases,
existing assays can be readily multiplexed if no competitive PCR
inhibition is experimentally evidenced, and uorophores with
spectrally distinct emission peaks are used.41 From an instru-
ment perspective, probe multiplexing requires either multiple
detectors, each equipped with its own detection range lter, or
a single detector mounted with a moving lter wheel equipped
with the relevant wavelength lters. Both solutions, however,
bear manufacturing cost and instrument reliability implica-
tions due to the requirement for multiple and/or moving parts,
which are ill-suited to eld deployment in resource-limited
countries. This makes a single detector approach lacking
ltering requirements, such as that proposed herein, a valuableas no impact on assay performance. Triplicate ABI7500 reactions with
NA extracted from AR14 EBOV surrogate (a), PV14 EBOV surrogate (b)
la virus NAAT standard (c) suggest retention of the template concen-
nt per reaction LLOD. To compare instrument performance (d), blood-
acts were carried out in parallel, demonstrating comparable reaction
s are shown in (a–c). Individual replicates are shown in (d), with the inset
(Y axis, 5500–10 500 AFU) obtained across 665–675 nm (X axis) at each
sponding to spectra across cycles 10–22.
Chem. Sci., 2017, 8, 7780–7797 | 7785
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View Article Onlinesolution. Although our modelling eﬀorts conrmed that
mathematical42,43 spectral unmixing allowed for concomitant
use of Quasar 670, Quasar 705 (duplex) and CAL635 (triplex; see
ESI†), multiplexing of the GP, NP and RP assays resulted in loss
of sensitivity. We therefore focused on demonstrating robust
proof of principle for the platform on a singleplex format and
opted for dening key multiplexing parameters through
computational modelling based on the highly reliable44 kinetic
spectral ratiometry45 method and the principles of the 2DDCt
approach46 (see ESI, Fig. S5†).
These modelling results justied the use of spectropho-
tometry in data acquisition for a blood-compatible point of care
instrument, as it would support both DNA stain high resolution
melting analysis assays and quantitative, multiplexed probe-
based assays. Consequently, our nal excitation/emission
detection array was determined to involve an Ocean Optics
Maya LSL tuned to detect all light in the range 600–800 nm. To
oﬀer the capacity for parallel, independent sample testing, the
instrument was also congured to oﬀer 8 independent sample
wells; this necessitated a custom octofurcated ber (Fig. 4a)
with a shared spectrophotometer end consisting of 8 0.22 NA,
low OH, 200 mm cored ber terminating in a single keyed SMA
connector attached to the spectrophotometer. In order to allow
random access and to facilitate the use of a single shared
spectrophotometer, each well was illuminated individually so
that any spectra observed could be attributed to a specic
sample. The emission/collection legs of the bers terminated at
one end at an individual 635 nm laser diode per reaction
position and the other located above the reaction vessel itself,
into a barrel lens for focusing and collimating the excitation
emission (Fig. 4b and c). The laser diode was built into
a housing with an SMA connector and 650 nm bandpass built in
to remove any excitation outside of the 635 nm laser line
(FB650-40, Thorlabs). A 650 nm longpass lter was built into the
entrance of the MAYA LSL to further lter unwanted laser light
from the resulting emission spectra.
To conrm that implementation of this emission/detection
chemistry and optics array would perform as expected, we
rst built a single well, Peltier-based thermal cycling testing rig
(Fig. 4b) around our spectrophotometric testing array. We also
mold-manufactured a custom designed reaction consumable,
molded from a thermally conductive (15 W m1 K1) carbon
loaded polypropylene compound consisting of 56% carbon (Lati
SpA, Vedano Olona, Italy) with an easy handling puck and cor-
responding clear optical lid (Fig. 4d) that reduced the thermal
energy requirements for freezing and rapid thermal cycling. The
vessel had an optically clear cap and top-down excitation/
emission measurement using the previously described reec-
tance probe.
We next proceeded to test the amplication eﬃciency for the
blood-compatible Trombley+ assay (Quasar 670/BHQ2 GP
probe) on AR14 RNA extracts across the diagnostic laboratory
standard ABI7500 instrument and consumables, vs. our testing
rig (Fig. 4b). As the ABI7500 uses onset of amplication
threshold cycle (Ct) calling as well as curve smoothening algo-
rithms,47 we developed a live Ct calling protocol based on real
time data processing using the raw uorescence values7786 | Chem. Sci., 2017, 8, 7780–7797obtained during the run. Data was rst baselined by averaging
the uorescence values observed in the 5 cycles prior to any
uorescence rise. These new values were then screened to
determine the highest uorescence observed in each channel
and a relative uorescence value for each well was determined
by dividing each cycles' observed uorescence values by this
maximum value and a graph of cycle against relative uores-
cence on a 0–100 scale was plotted. The cycle number at which
a 10% increase in uorescence over baseline was taken as the
Ct. The results indicated comparable reaction rates and Ct
values across the two platforms (Ct 9.50 and 10.5, respectively;
Fig. 3d), despite the markedly diﬀerent reaction volumes,
consumable thermal properties, ramping rates, instrument
optics and signal processing algorithms, supporting further use
of this real time thermal cycling system.Single chamber, phase transition, blood-compatible RT-qPCR
with no pre-processing
Phase transition, such as ice crystal formation during freezing,
can release intracellular contents by disrupting cytosolic and
nuclear membranes. Protein denaturation at high temperatures
can also disrupt ribonucleoprotein complexes, thereby
releasing nucleic acids for analytical assays. Used together, it
has been proposed that the two processes might enable access
to bacterial DNA templates for real time PCR in a single
chamber system without the need for any biological sample pre-
processing (WO/2011/157989). We hypothesized that these
processes would also stress viral particle structures adequately
to allow for RT-PCR detection of viral RNA in a single reaction
chamber.
We sought to test the hypothesis with MS2 coliphage virions
(Armored RNA®), reasoning that proof of principle on such
a robust template would likely extend to lipid-enveloped viruses
and the more fragile Filoviruses.22 Manual preliminary experi-
ments suggested 10 cycles of freezing and 95 C denaturation
were optimal for releasing RNA from MS2 virions, but that the
high levels of RNase activity in biouids between ambient
temperatures and 85 C (ref. 48 and 49) should be avoided (see
ESI; Fig. S6†). We therefore decided to carry out further exper-
iments using automated thermal cycling capable of reaching
20 C, and replaced 95 C denaturation with simple thawing.
This would also allow us to further examine whether denatur-
ation was indeed essential in releasing viral RNA genomes from
MS2 virions, for them to be accessed by reverse transcriptase.
Thus, we assembled a Peltier thermal cycling rig around the
custom blood-compatible spectrophotometric emission/
detection array used in our earlier experiments, modied
through use of a heat removal module (HRM). This is a uid
cooled heatsink whereby the uid, in this case at 35 C, is held
at a temperature intermediate of the PCR extension tempera-
ture and the freezing point (WO2010010361) to enable rapid
20 C cooling. This relies on high levels of thermal isolation of
the heatsink from the sample such that the DT of the Peltier can
be relied upon to drive the reaction uid to in excess of 50 C
below that of the HRM and hence make possible freezing in
higher temperature environments. In these tests, we also usedThis journal is © The Royal Society of Chemistry 2017
Fig. 4 TheQuRapID platform. A custom octofurcated ﬁbre shares a single spectrophotometer end across 8 separate laser diodes and 8 separate
optical heads (a) to allow for medium throughput through 8 independently operated, random access workstations (b). The workstation contains
the Peltier assay station connected to a temperature controller operated by a Raspberry Pi, which is connected to the laser diodes for light
emission and the spectrophotometer for data acquisition and processing, whilst being operated by a touch screen compatible with personal
protective gloves (c). Each assay station accepts a single, custom fabricated, disposable puck sealed with a custom optical lid designed for easy
handling (d). The resulting 20 kg, QuRapID instrument is a tabletop-sized device powered by a car alternator, car battery or mains electricity
featuring eight independently operated assay stations, with software designed for simple (video online) end-user interaction in full personal
protective equipment, suited for ﬁeld deployment in a ruggedized case and medium throughput testing in a laboratory infrastructure-free
manner (e).
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View Article Onlinethe Trombley+ assay and 105 GE of our custom-manufactured
AR14 EBOV Armored RNA® MS2 coliphage construct. Finally,
given our results on RT-PCR enzyme tolerance for blood, we
performed this test with the ABI Fast virus master mix, which is
used in the EZ1 diagnostic assay. With the device achieving
overall sample-to-answer in 70 minutes ahead of any additionalThis journal is © The Royal Society of Chemistry 2017RT-PCR thermal cycling timing optimization beyond the stan-
dard Taqman® cycling timings used in the EZ1 assay, these
results reproduced the outcome of the manual study, identi-
fying 8–10 freeze–thaw cycles as the optimal viral particle
disruption range (Fig. 5a, S7A and B†). Moreover, the experi-
ment conrmed that denaturation was not necessary forChem. Sci., 2017, 8, 7780–7797 | 7787
Fig. 5 Optimised, controlled freeze–thawing of RNA viruses in probe-based qRT-PCR containing blood or serum. (a) Optimal freeze–thaw
extraction of RNA from viruses within qRT-PCR master mixes in the same reaction vessel is achieved with 8–10 freeze–thaw cycles as deter-
mined through threshold cycle (Ct) detection of template ampliﬁcation using the Trombley+ GP assay against 105 GE per reaction of AR14
templates. No blood was used in these reactions. (b) Increasing amounts of blood spiked into reactions containing 6.6  108 GE per reaction
AR14 subjected to 10 automated freeze–thaw cycles results in a 2 Ct drop in GP Trombley+ assay performance (4) against reactions containing
no blood. The Ct call in the absence of blood in the reaction (0% v/v ﬁnal blood concentration) is used as an optimal performance reference. (c)
Ampliﬁcation discrimination for the Trombley+ assay between no template control (NTC) reactions, and reactions containing 66 GE of AR14.
Reactions were spiked with 5 microliters of human blood (8% v/v ﬁnal blood concentration in the reaction) and viral genomes were extracted in
the qRT-PCR blood-containing mix using 8 freeze–thaw cycles. (d) Ten-fold serial dilutions in tissue culture media of tissue cultured derived,
700 PFU per ml Ebola virus were tested in three independent reactions using the Trombley+ GP assay. Fetal bovine serum was spiked into these
reactions as a fresh patient sample matrix surrogate, to an 8% v/v ﬁnal concentration. (e) Calibration of Ebola virus sample PFUs against GE
content, as independently determined on the QuRapID under BSL4 testing using AR14 pre-qualiﬁcation runs, reveals strong linear concordance
between two Ebola virus strains diluted in FBS and the ArmoredRNA surrogate template (99.96% probability of single curve ﬁt, Akaike's Infor-
mative Criteria test; individual replicates and 95% conﬁdence bands shown).
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View Article Onlineaccessing viral nucleic acids for this form of viral particle
disruption, even for the highly robust MS2 coliphage virions.
We therefore proceeded next to examine Trombley+ assay
tolerance for blood by progressively increasing blood input
from 0% to 10% v/v in reactions containing 6.6  108 GE per
reaction AR14 (Fig. 5b, S7C and D†). Thus, with the blood-free
reactions returning a Ct of 15, an <128 loss of signal (Ct of
22) was observed at low blood concentrations; however, the
trend was reversed to peak at 8% v/v blood with only a 4 signal
loss (i.e. Ct 17). Crucially, this small signal loss only aﬀected the
assay lower limit of quantication (LLOQ; Fig. 5c), as 66, and 67788 | Chem. Sci., 2017, 8, 7780–7797GE of AR14 were successfully discriminated from a no template,
8% v/v blood-containing reaction, but the two positive samples
were indistinguishable between them. These results indicated
that, although quantication at the lower end of the Trombley+
assay could be compromised in the presence of blood, detection
could still be reliably achieved. On the basis of the 1.4  104
PFU per ml whole blood detection limit for the laboratory-based
Trombley assay,9 we reasoned that use of 5 microliters of whole
blood in our method, i.e. 70 PFUs per reaction in a volume
compatible with digital venipuncture, would match the perfor-
mance of the laboratory method whilst remaining above theThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinelimit of quantication exhibited experimentally. Thus, the total
reaction volume for our method was nalized at 62.5 ml con-
taining a 5 ml blood sample (8% v/v). To determine whether
accurate sampling at this scale could take in the place in the
eld we evaluated a range of IVD-grade, graduated plastic
capillary samplers to observe a <3% standard deviation in 5 ml
collection with the Pasteur pipette-like MicroSafe® capillaries (n
¼ 20). This was conducted by operators wearing BSL4 personal
protective equipment comparable to that used by frontline
healthcare workers in triage centers.
Having achieved an assay chemistry, detection system and
sample volume predicted to match the diagnostic reliability of
the laboratory-based Trombley assay, we proceeded to construct
a prototype point-of-care instrument (Fig. 4d). Importantly, this
was designed for use in triage scenarios e.g. in emergency
response primary care centers or in the vehicles of mobile
outbreak response teams seeking to Quantitatively, Rapidly
Identify (QuRapID) EBOV disease in symptomatic patients
either oﬀmains power or a car alternator power source. Initially
designed as a lightweight, A4-foot print format, the nal, 20 kg
tabletop prototype sought to reduce the risk of unauthorized
removal from triage centres and ensure robustness during
transportation in e.g. oﬀ-road settings. In addition, this tabletop
instrument featured 8 random access assay stations to allow for
independent, parallel operation and a touch screen interface
compatible with gloves. A SOP was also devised (ESI video
online and Fig. S8†) in line with the simplicity necessary for
minimally trained frontline staﬀ focusing on patient care in
a high stress environment whilst in full personal protective
equipment. This included consumables design, automated
buﬀer dispensing and secured thermal cycling that would
minimize risk of environmental contamination, operator error
or accidental sample release.Analytical sensitivity and specicity testing with live Ebola
virus
With the outbreak ending by this time (November 2015) and the
very limited number of new cases, the means for delivering
evidence of clinical relevance with live EBOV were restricted to
either stored samples or culture-derived EBOV tested in simu-
lated patient samples. Previous reports indicated stored blood
samples impacted eﬃcient completion of PCR,18,25 which
motivated us to seek samples stored in the absence of additives
known to impact PCR. However, anecdotal evidence indicated
substantial operator variability in sampling and storage proce-
dures throughout the West African outbreak. Therefore, to
minimize the impact of such variability inherent to stored
samples vs. what should be a minimal, direct sample analysis
process, we elected to proceed with BSL4 laboratory testing with
a range of live, culture-derived Filoviruses. On the other hand,
collection of fresh human blood by digital venipuncture was
prohibited in BSL4 for health and safety reasons. As a result,
fetal bovine serum (FBS) obtained without the use of anticoag-
ulants or preservatives was used as a surrogate biological matrix
to human blood. In doing so, we also acknowledged that direct
volume substitution of blood with serum would double the nalThis journal is © The Royal Society of Chemistry 2017concentration of serum components in our reactions, doubling
in parallel their PCR inhibitory eﬀects.
Thus, the performance of the blood-compatible Trombley+
GP assay (Quasar 670/BHQ2) in ABI Fast virus master mix and
our QuRapID prototype was evaluated against the Trombley/
ABI7500 FAST gold standard SOP with the same mastermix,
the FAM-labelled GP assay, and a variety of Filoviruses (Table
S2†). Aer undertaking assay transfer to BSL4 and pre-
qualication with our AR14 standards (Fig. 5d and S7E†),
infectious, culture-propagated Filoviruses were serially
diluted and tested at each resulting concentration on the
QuRapID. Alternatively, the serially diluted viruses were
extracted, puried and assayed according to the EZ1 assay
SOP. The results indicated the Trombley+/QuRapID system
could detect as little as a 1.4  103 PFU per ml whole blood-
equivalent of live EBOV Yambuka Ecran (Fig. 5d and S7F†),
with a LLOQ of 1.4  104 PFU per ml whole blood-equivalent.
More importantly, however, performance across capsid
surrogate viruses, EBOV Yambuka-Ecran and EBOV Makona
Guinea was consistent in terms of the analyte that is quanti-
ed by RT-qPCR i.e. genome equivalents, rather than the
number of viable virions (Fig. 5e). Crucially, no false positives
were encountered across template-free controls or any of the
genetically related viruses, conrming that the analytical
specicity of the assay7,9 had not been compromised in the
presence of FBS and uorophore migration to far red spectra.
Furthermore, these data were obtained through independent
experiments carried out across seven days using multiple,
separate virus types and batches. Nevertheless, and despite
the propensity of PCR technologies for manual error, the
results followed a log-linear relationship of virus genome
concentration to Ct call, with 99.96% probability of single
curve t, at a linear regression R2 of 0.9967. These results
indicated that assay performance and relative quantication
could be pre-calibrated using MS2 Coliphage under BSL2
safety standards, with the inhibitory eﬀect of FBS (and blood)
not aﬀecting assay linearity.
On this basis, to further investigate the extent to which the
data generated by the two platforms were indeed comparable,
we independently calibrated each dataset against standard
curves generated using AR14, and calculated the unknown
lovirus stock concentration in GE per ml. This analysis
further indicated that the QuRapID platform returned data
comparable to the gold standard lab-based Trombley method
(Table 1). However, it also highlighted that where use of
manual extraction/purication might be more sensitive to
non-infectious viral genomes through analyte stabilisation,
the QuRapID whole blood assay might be less so. Thus, the
number of viral genomes to viable virions (log10 GE/log10 PFU
ratio) for EBOV Yambuka-Ecran was higher than that of the
younger EBOV Guinea Makona isolate irrespective of the
platform used, but consistently lower on the QuRapID. These
results were in line with separate reports9,13,50 which have
suggested virus more extensively passaged in vitro might
produce fewer infectious virions vs. newer isolates, thereby
increasing the ratio of genomes to infectious particles in
a biouid.Chem. Sci., 2017, 8, 7780–7797 | 7789
Table 1 Comparative performance of manual vs. QuRapID-based quantiﬁcation of live Ebola virus
Strain
Ebola virus amount
Genome/virion ratio
(log GE/log PFU)
Live virions (log PFU per ml)
Genomes
(log GE per ml)
ABIa QuRapIDb ABIa QuRapIDb
Zaire ebolavirus Yambuka-Ecran (1976) 6.85 9.68 9.39 1.41 1.37
Zaire ebolavirus Guinea Makona (2014) 8.32 9.26 8.27 1.113 0.994
a Calibrated against quantied AR14 on the ABI7500 (ABI). b Calibrated against quantied AR14 on the QuRapID (QR).
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View Article OnlineDiscussion
The socioeconomic value of molecular diagnostics in contain-
ing highly infectious disease has been convincingly demon-
strated in the West and concurrent Central/East African EBOV
outbreaks,51 and the South Korean Middle East Respiratory
Syndrome Coronavirus (MERS-CoV) outbreak.52 Furthermore,
historical data causally link international travel and mass
attendance events with pandemic transmission.53 Therefore the
capacity to deploy appropriate, reliable and cost-eﬀective diag-
nostic capability is an international public health requirement.
Yet, to date, there exists no true point of need solution suitable
for mass screening that can support eﬀective containment at
international ports of entry or outbreak triage centers etc., with
minimal economic burden, transportation and international
trade disruption. Indeed, we expect no such single system to
prove of universal utility given transmission, symptomatology
and carrier status may diﬀer vastly depending on the biology of
each pathogen and thus be best detectable through use of
distinct analytical procedures. Rather, a exible approach needs
to be adopted, centered on responding rapidly, implementing
appropriate technologies and proportionate procedures rele-
vant to key factors to patient presentation and disease dissem-
ination. Thus, whilst many highly infectious viral diseases may
disseminate through asymptomatic carriers, EBOV trans-
mission requires viraemia whose levels correlate with symptom
intensity and indeed survival potential.9,10,54,55 As a result, many
eﬀorts have been made to detect pre-symptomatic levels of
EBOV infection,56 with several anecdotal reports of various
NAATs detecting pre-symptomatic individuals in the course of
their evaluation during the West African outbreak. At present,
however, themost reliable evidence thereto pertains to an 8-plex
host microRNA biomarker signature detectable by NAAT in
blood plasma.57 However, this has only a 50% pre-symptomatic,
and a relatively low 86% infection status classication potential.
Therefore, reliable containment of future EBOV outbreaks will
pivot on eﬀective detection and screening of symptomatic
individuals. Crucially, such EBOV positive patients typically
present with viraemia levels well in excess of 105 GE per ml of
whole blood, i.e. some 2–4 orders of magnitude above of the
LLOD of the Trombley and other RT-qPCR assays, as demon-
strated in multiple studies during the West African4,55,58,59 as
well as historical outbreaks.3–5,607790 | Chem. Sci., 2017, 8, 7780–7797Of the diagnostic solutions proposed for EBOV and other
infectious diseases, the most advanced, minimal end-user input
technologies include antibody lateral ow tests61 and semi-
automated NAATs.10,17 The latter, however, remain the most
reliable and robust methods for diagnosing EBOV in viraemic
patients,9,10,54 with antibody systems suited to exclusion
screening in cadavers or patients exhibiting intense symp-
toms.62 Yet both NAATs used for diagnostic purposes in West
Africa7,63 required mobile laboratory deployments.2 Thus, the
benchtop BioMe´rieux BioFire® FilmArray and Cepheid Gen-
eXpert® NAATs received WHO and/or FDA EUA during the West
African outbreak. Both instruments require basic laboratory
infrastructure, are semi-quantitative, multiplexing-compatible
and up to eight times faster than the manual Trombley
method. Whilst BioFire® oﬀers FDA-approved, diﬀerential
diagnosis at a cost of US$150 per test, GeneXpert® assays for
single agents at US$20 and oﬀers medium throughput
through scalable devices. In both cases, however, sample pro-
cessing still requires exible-lm isolator containment, tech-
nical expertise pertaining to the manual steps involved, and
know-how related to data interpretation. Nonetheless,
together, these solutions allow for index case causal agent
identication and provide some capacity for screening, albeit
still in a laboratory setting and at considerable cost largely due
to microuidics and/or pumps which mechanise as many
manual procedures as possible. Thus, overall, BioFire® tests are
comparably priced to laboratory-based Trombley assays,
whereas the GeneXpert® EBOV test remains up to twice more
expensive than the annual per capita healthcare spend in West
Africa, despite charitable development funding and ex-works
pricing as negotiated by FIND Diagnostics on behalf of the
WHO, substantially reimbursed by the Gates Foundation.
Importantly, the recently announced, portable GeneXpert®
Omni oﬀers single sample analysis capacity albeit with no
improvement in sample-to-data turnaround (2 hours), ques-
tioning its mass screening utility. Moreover, both systems are
‘closed access’, meaning public health authorities cannot
independently respond to emerging threats by rapidly tran-
sitioning their in-house developed assays to such disseminated
use platforms: tellingly, the Trombley assay received FDA EUA
days aer the WHO PHEIC declaration, whereas the Cepheid
platform required several months of additional development.
Elsewhere, emerging alternative NAAT solutions focus on the
energy eﬃciency of isothermal amplication technologies64 asThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinewell as the agnostic, de novo analytical power of memory stick-
sized sequencing systems.65,66 Whilst many of these have been
successfully evaluated in resource-limited settings,64,65 these
solutions still require extensive and costly laboratory infra-
structure for sample pre-processing64–66 even onto genome
extraction,65,66 are non-quantitative,64 closed access,64,66 or
require high bandwidth data transfer/computational power
access65,66 to realize their potential.
In this work, we have demonstrated that controlled, low
temperature freeze–thawing of viruses as structurally diverse as
MS2 coliphage (Armored RNA®) and EBOV can release virion
genomes within a complex biouid matrix such as serum or
fresh blood. Furthermore, we have evidenced that simple
substitution of commonly used green DNA stains and probe
dyes with red/far red uorophores spectrally compatible with
blood eliminates uorogenic inhibition in RT-qPCR. Unlike
previous reports involving various formats of stabilized
blood,18,19,25 in our hands, use of freshly obtained blood, e.g. by
digital venipuncture, did not appear to extensively or entirely
inhibit PCR. More importantly, combination of controlled
freeze/thawing with far red uorophores and simple RT-qPCR
enzyme formulations was found to be reliable enough to
adequately and co-linearly detect specic genetic targets across
at least two classes of viruses, assayed on separate days. To our
knowledge this is the rst use of pre-calibration standards for
RT-qPCR-mediated sample quantication, directly in whole
blood, across a wide dynamic range, with minimal impact on
sensitivity and no impact on diagnostic specicity. Thus, the 1.4
 104 PFU per ml of whole blood equivalent detection limit for
the Trombley+ assay on the QuRapID platform is approximately
one order of magnitude higher than the detection limit of the
gold standard laboratory-based Trombley/ABI7500 test. At rst
glance this might appear too great a diﬀerence between a novel
and a gold standard platform. However, the Trombley+/
QuRapID LLOD is comparable to the independently reported
LLOQ of the Trombley/ABI7500 gold standard at 1.2  104 PFU
per ml.9 Nonetheless, this metric does not relate to viral
genomes, the analyte detected by both assays. Rather, perfor-
mance qualication is expressed relative to the concentration of
viable, infectious viral particles, which are impossible to
quantify by RT-qPCR. However, both our data and the latest
independent Trombley assay performance report,9 present GE/
PFU ratios: this makes direct comparisons acceptable across
the studies, laboratories and platforms. Thus, in the context of
the 1  105 GE per ml or greater viraemia levels exhibited by
symptomatic EBOV patients,3–5,55,58–60 our results evidence clin-
ical utility for our proposed approach to meet demand during
future EBOV outbreaks, subject to completion of the necessary
EUA qualication studies. Moreover, as EBOV caches in the
cerebrospinal uid of survivors and may lead to meningoen-
chephalitis,67 we have also briey examined whether our
method is compatible with this biouid. Thus, we observed no
eﬀect from blood contamination on Trombley+/QuRapID Ct
calls aer spiking AR14 at 1  108 GE into reactions containing
10% v/v human cerebrospinal uid (Fig. S9†). The approach
may therefore oﬀer utility beyond symptomatic EBOV diag-
nosis, not only to other infectious viral disease with viraemiaThis journal is © The Royal Society of Chemistry 2017levels relevant to the detection limits of our methodology, but
also to the rapid and economic detection of the causes of
meningitis where time-to-diagnosis through 3 day-long, clas-
sical clinical microbiology might be disadvantageous. Most
importantly, however, unlike many other approaches, the
performance we report with this novel platform is achieved with
700 less blood volume than the standard 3.5 ml needed for the
gold standard Trombley assay. Studies are therefore underway
to explore whether large volume PCR68 accommodating higher
amounts of patient sample at the point of care might meet and
even exceed the sensitivity of the EZ1 SOP.
Beyond sensitivity and specicity, in line with the ASSURED
criteria,16 key to disseminated use of novel technologies, and
especially in resource limited settings, is test aﬀordability. In its
present, diagnostically relevant, 62.5 ml reaction format,
disposables for the Trombley+ assay on the QuRapID cost
US$12.50 per test before scale up or subsidy, an amount rele-
vant to developing nations and competitive to emerging elec-
tricity-free,69 or disposable isothermal NAAT that rely on
complex fabrication methods.70 Thus, in the context of powered
point-of-need solutions, the 2 minute, 10 cycle freeze/thaw
process implemented in our approach adds only an additional
24 watts of energy requirement per test. This can be nonetheless
additionally managed through smart thermal load sharing
between active stations operating ad hoc, thereby reducing
overall energy requirements during screening use. Moreover,
the overhead is eﬀectively compensated by the lack of any
motorized, expensive consumables or instrument parts that
could otherwise compromise instrument robustness. To extend
this principle to overall process user-friendliness, we have
additionally minimized to the greatest extent possible the
manual steps involved in conducting RT-qPCR (ESI video
online†) without recourse to laboratory infrastructure or intro-
duction of manufacturing complexity. Thus, the standard
operating procedure we devised involves a disposable
consumable, pre-loaded with lyophilized reagents and an
automated, pre-calibrated 57.5 ml solvent dispenser to eliminate
the need for refrigeration. Although the ABI Fast RT-qPCR
mastermix we tested against live EBOV is not in itself
amenable to lyophilisation, refrigeration-free RT-qPCR master-
mix production is possible71 and commercially available for
research and diagnostic purposes. To this end, we have
screened and identied a proprietary, lyophilisation- and blood-
compatible formulation, successfully dried and tested it as part
of this work; this formulation is presently under development to
match the wet assay performance characteristics reported
herein.
An essential requirement in any diagnostic technology,
particularly for hazard group 4 pathogens, however, is safety:
this takes the form of both operator safety and diagnostic reli-
ability. Although the use of a exible lm isolator for the
QuRapID instrument would be subject to local health and safety
requirements in an ‘orange’ or ‘red’ triage zone, IVD-marked,
low operator risk, sheathed lancets for digital venipuncture
are readily and cheaply available over the counter e.g. for use
with point of care glucometers. In our hands, these can be safely
handled in full personal protective equipment suitable forChem. Sci., 2017, 8, 7780–7797 | 7791
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View Article Onlinehazard group 4 pathogens. Use of plastic capillaries, such as the
low error rate 5 ml Microsafe® trialed herein, can also eliminate
the risk of injury or instrument contamination beyond the puck
consumable. Similarly, the optical lid is additionally secured in
place on the QuRapID during thermal cycling by the weight of
the top-down detector, which is itself magnetically held in
place. Thus, aer process completion, all consumables can be
disposed of as hazardous clinical waste, and the instrument can
be wiped down or indeed fumigated. Crucially, no instrument,
electronics or optics damage or failure was observed aer
fumigation and exit of our prototype QuRapID platform from
BSL4 containment aer testing with live EBOV. Therefore, the
platform retains the mobility and repeated utility requirement
pertinent to rapid response in outbreak scenarios.
On the other hand, experimental evidence is required sup-
porting accurate detection of multiplexed RT-qPCR to support
safe calling of process and diagnostic success during use of this
technology. Unfortunately, in our hands, the singleplex
Trombley assays and the RP control assay exhibited competitive
inhibition at the lower end of analyte concentration. Reasoning
that altering even primer and probe concentrations would
require re-qualication of assay specicity, we decided instead
to conrm the utility of our approach against EBOV genome
detection in singleplex mode. Nevertheless, the resulting uo-
rimetric data were used to examine state of the art mathemat-
ical deconvolution approaches used in other optical platforms
operating in the same spectral ranges. This analysis indicated
that separation of commercially available probe uorophores in
the 600–750 nm range is adequately assayed spectrophotomet-
rically, and that the signal to noise ratio of a uorophore might
direct its use in a multiplexed fashion. Thus, an example dye
trio consisting of CAL635, Quasar 670 and Quasar 705 could
enable migration of an established triplex assay to the far red,
blood-compatible spectrum, but the signal to noise ratio of
Quasar 705 in the context of blood would make this uorophore
suitable only for the detection of a high copy number control.
Encouragingly, the spectral data obtained throughout these
studies with Quasar 670-labelled probes are in line with our
predictive modelling eﬀorts regarding peak ratiometry. Thus,
uorigenic data normalization clearly exhibits adequate assay
window in reliably detecting emission peak changes as no
deviation in ratiometric proles was detected for Quasar 670
relative to other dye emission peaks. Eﬀorts are thus underway
to implement automated Ct calling in multiplex mode as well as
viral genome quantication through reagent pre-calibration
based on our observations across AR14 and the two distinct
EBOV strains we tested. Overall, whether substitution of probe-
based detection chemistry with DNA stains and high-resolution
melt will enable further cost reductions in the future will largely
depend on the relative diagnostic reliability, computational,
and energy requirements of the two approaches when used in
the presence of blood vs. already available, highly reliable probe
assays.
In this context, in response to the 2015 MERS-CoV South
Korean outbreak, time-to-transfer for an established probe
chemistry assay onto the QuRapID platform and far red, blood-
compatible chemistries was calculated at six to eight weeks,7792 | Chem. Sci., 2017, 8, 7780–7797with rate limiting steps being (a) surrogate BSL2 template
production, and (b) reagent synthesis. Thus, stockpiling
notwithstanding, we estimate that BSL4 laboratories with
robust reagent supply chains could independently deliver mass
screening, mass production-ready assays within a fortnight. The
limited impact of established assay migration to blood-
compatible chemistries observed herein, coupled to readily
available, high condence computational assay design capa-
bility and parallel screening capacity even suggests utility
against pathogen genomic dri, to enable rapid response for
newly identied pathogens.
Experimental
Primers, probes and uorescent dyes
We focused on the Trombley primer and probe sets for the
EBOV GP and NP genes,7,9,10 considering the human RP assay as
a control,8 and an MS2 Escherichia coli phage-specic assay
set72,73 for uorescent probe- or intercalator-based blood toler-
ance studies (SYBR Green I; Thermo Fischer Scientic, War-
rington, UK). Primers (Table S3†) were synthesized by
Integrated DNA Technologies (Leuven, Belgium). Probes were
purchased from Thermo Fisher Scientic (FAM), IDT-DNA
(FAM, Cy5; Leuven, Belgium), and LGC BioSearch Technolo-
gies Ltd. (Quasar; Belfast, UK). Computational PCR perfor-
mance analysis was carried out using VisualOMP™ v.6.3 (DNA
Soware, Ann Arbor, MI, USA). Fluorophores were purchased
from Thermo Fisher Scientic (instrument calibration, 1,2-
diamino-4,5-dimethoxybenzene (DDB), and SYTO®), Fluoro-
genics Ltd. (Viridian Red), and LGC BioSearch Ltd. (ATTO and
CAL635 dyes).
RT-qPCR blood tolerance experiments
To determine the tolerance of commercially available RT and
PCR enzymes to blood, one-step reaction master mixes were
assembled on wet ice using GoTaq® G2 Hot Start polymerase
(Promega; Southampton, UK) in GoTaq® G2 Hot Start Colorless
Master Mix (Promega) supplemented with 5 units of GoScript®
Moloney Murine Leukemia Virus reverse transcriptase (Prom-
ega), primers and probes/dyes at concentrations as previously
published.6,27 Duplicate aliquots were dispensed, and supple-
mented with blood and nuclease-free water (Promega) to ach-
ieve the nal blood concentrations indicated. Template was
added last in each aliquot to achieve a 50 ml nal reaction
volume ahead of commencing thermal cycling on an Illumina
Eco™ running Eco™ Soware v.4.0.7.0 (Illumina Inc., San
Diego, CA, USA).
Surrogate virus standards and biological matrices
To enable accelerated development under biosafety level 2
(BSL2) we used a Hepatitis C Virus74 (HCV) Armored RNA
Quant® (Asuragen, Inc., Austin, TX, USA; manual phase
disruption studies) as an MS2 coliphage virion model and three
EBOV surrogates (Table S2†): a custom Armored RNA Quant®
(AR14; 10 (ref. 12) GE per ml stock concentration quantied
against synthetic RNA templates by RT-qPCR) and two, in-houseThis journal is © The Royal Society of Chemistry 2017
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View Article Onlineproduced, pseudotyped lentiviruses. These surrogates featured
RNA genomes engineered to contain the concatenated target
sites for the Trombley GP and NP assays as encoded in the 1976
Yambuka-Ecran EBOV (PV76) or 2014 Guinea Makona (PV14;
AR14).
To generate these recombinant lentiviruses, assay targets
anked by BamHI and NotI (Geneart plasmids, Thermo Fisher
Scientic) were sub-cloned23 into the transfer plasmid pDUAL-
eGFP (a gi from David Escors, University College London).
Lentiviruses were assembled in HEK293T cells grown in 10% v/v
fetal bovine serum (FBS)-supplemented Dulbecco's Modied
Eagle Medium (DMEM; Thermo Fisher Scientic), 5% v/v CO2,
37 C, using a second-generation method involving 1 mg per ml
polyethylenimine (Sigma Aldrich, Dorset, UK) co-transfection
with pMD2.G (a gi from Didier Trono; Addgene plasmid
#12259) carrying the envelope protein for vesicular stomatitis
virus, and p8.91 encoding the lentiviral core genes,75 at
a plasmid ratio of 1 : 1 : 1.5, respectively. Supernatants were
replaced with 6 mL fresh media at 16 hours and 0.45 mm lter-
harvested at 40 hours for 4 C storage. Cells were fed with fresh
media (5 ml) and Lentivirus was lter-harvested again at 64
hours, pooled, concentrated (4000  g, 4 C, 16 hours), re-
suspended in 1.0 mL DMEM, re-centrifuged through a 5 ml,
20% w/v sucrose cushion and re-suspended in 1.0 ml DMEM for
80 C storage. Yields (viral particle per ml (vp per ml) or
genome equivalent per ml (GE per ml)) were derived using
a Nanosight NS300 (Malvern Instruments, Malvern, UK) aer
1 : 10 dilution in 10% v/v FBS-supplemented DMEM or inter-
polation against standard curves of AR14 RNA extracts by
Trombley assay for the PV76 and PV14 constructs, respectively.
RNA extracts were obtained using the QIAamp Viral RNA Mini
Kit (Qiagen, Manchester, UK), according to the manufacturer's
instructions, assuming 100% extraction eﬃciency.
Fresh human blood was aseptically obtained by digital ven-
upucture of healthy adult male volunteers (Vitrex® Sterilance®
LiteII lancets, VWR, Lutterworth, UK), as approved under the
University of Westminster Research Ethics Committee (appli-
cation no. VRE1415-0171, 7th Nov. 2014). Informed consent was
obtained for any experimentation with human subjects. Cere-
brospinal uid (CSF) was kindly provided by Prof. T. Solomon
(University of Liverpool). Patient samples were simulated under
BSL4 using FBS (Thermo Fisher Scientic).Trombley assay transfer
Plate-based RT-qPCR assays were carried out on an ABI7500
(Thermo Fisher Scientic) in accordance with the manufac-
turer's SOP specied for the EZ1 assay. Briey, aer extraction/
purication using the QIAamp Viral RNA Mini Kit into 70 ml
eluents, RNA was serially diluted using nuclease-free water
(Qiagen, Manchester, UK). Trombley assay one-step RT-qPCR7
was carried out on 5 ml samples in ABI Fast virus master mix
(Thermo Fisher Scientic) at 20 ml nal reaction volumes.
Factional threshold cycle (Ct) values were obtained using the
7500 ABI soware (v.2.3), implementing onset of amplication
Ct calls. Performance metrics were derived on technical tripli-
cates using electronic pipettes: data were represented as meansThis journal is © The Royal Society of Chemistry 2017 95% condence bands (LDR testing) or triplicate average 
standard deviation, unless otherwise specied.
QuRapID instrumentation
Pre-prototype work on phase transition was carried out using
manual acetone/dry ice bath to 105 C dry block cycling of
standard 0.2 ml PCR tubes (Thermo Fisher Scientic). Sample
temperature was measured in separate tubes loaded with equal
volume mock samples and an alcohol thermometer to monitor
ramping and hold rates. Instrument and soware development
of the novel QuRapID (Fig. 4d) thermal cycler (WO/2011/157989)
involved a Raspberry Pi (Raspberry Pi Foundation, Cambridge,
UK)-controlled, single-well prototype (Fig. 4c) with custom-
fabricated thermal control printed circuit boards, to evaluate
the complete Luxeon Rebel range of light emitting diodes
(Lumileds, Amsterdam, Holland), ltered white light sources
and laser diodes (Osram, Regensburg, Germany). Performance
testing was carried out on two separate 8-well instruments in
three separate laboratories (University of Westminster, BioGene
Ltd. and Public Health England). Fluorophore and probe dye/
quencher compatibility with blood was assessed in duplicate
by adding 4–5ml of blood directly into a reaction master mix
(50 ml nal volume). Results were expressed as the absolute
uorescence, and summarized as the diﬀerence in uorescence
(positive or negative) in the presence and absence of blood aer
background-subtraction. Emission peaks were dened as the
wavelength with the highest emission intensity for each dye,
with peak emission intensity dened as the average intensity at
1 nm from the specic wavelength (11 values total). Signal to
noise ratios were calculated against the blood sample readings
within the same wavelength region as dened by the dye
measurements in the presence of blood. Threshold values were
calculated as 1.5 standard deviations above the emission peak
average intensity in the dye-free, blood background samples.
Data processing was carried out on Microso Excel (v.15;
Microso, Reading, UK) and graphical representation was per-
formed on Microso Excel or GraphPad Prizm v.7.0a (San
Diego, CA, USA). The end-user-directed SOP (video online)
based on a 62.5 ml nal reaction volume and 5 ml fresh blood
samples (8% v/v nal blood concentration in the reaction) is
summarized in Fig. S7.†
Biosafety level 4 (BSL4) sensitivity and specicity testing
The infectious viruses evaluated in this study (Table S2†) were
specic stocks produced at the Porton Down BSL4 laboratory of
Public Health England. Live viruses were quantied by titration
to obtain 50% tissue culture infectious dose (TCID50) in VeroE6
cells (European Collection of Cell Cultures, UK) and titers were
converted to PFU per ml by multiplying the TCID50/ml values by
0.7 assuming Poisson distribution.11
All live virus manipulations and QuRapID analyses were
performed under BSL4 across 7 separate days including
instrument pre-calibration runs on AR14. Live viruses were
serially diluted 10-fold in FBS or minimal essential medium
plus GlutaMax™-I (MEM; Thermo Fisher Scientic) and used as
templates for the QuRapID-migrated Trombley GP assayChem. Sci., 2017, 8, 7780–7797 | 7793
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View Article Online(Trombley+ assay). Reactions comprised of 57.5 ml RT-qPCR
master-mix (TaqMan® Fast Virus 1-Step Master Mix (Thermo
Fisher Scientic), primers, and probes (Table S3†)), to which
5 ml of FBS-diluted virus or 4 ml FBS and 1 ml of MEM-diluted
virus were directly added. Assay performance was expressed as
Ct call against titration-derived infectious virus concentration
in PFU per ml or genome content in GE per ml based on AR14
pre-calibration.
Independent samples across the two virus dilution series
(140 ml per dilution) were chemically inactivated in accordance
with PHE's hazard group 4 inactivation methods. Sample tubes
were disinfected with detergent in accordance with PHE's BSL4
disinfection policy for safe working of material at BSL2. RNA
was extracted using the QIAamp Viral RNA Mini Kit (Qiagen)
and quantied against RNA extract standard curves from AR14
using an Applied Biosystems 7500 Fast (Thermo Fisher Scien-
tic). Primer and probe sets specic to Filoviruses other than
EBOV were used in specicity tests (Table S3†). Stock virion
concentration in GE per ml was quantied as the titration range
average, as calculated per analytical platform.Statistical methods
Linear regression analyses to dene assay LDR were conducted
on GraphPad Prizm on the means of technical triplicates, with
95% condence bands graphically represented across the
titration range tested. The probability of single curve t for
independent assays or assay templates was determined by
Akaike's Informative Criteria Test conducted on blinded sample
data using GraphPad Prizm. Diagnostic parameters were
determined in accordance to Armbruster and Pry.76Authors contributions
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